Lynn M. Abell

机构：Bristol-Myers Squibb (United States)

发表论文 51 篇 · 总被引 1324 次 · h-index 22

代表论文

• Immune-modulating enzyme indoleamine 2,3-dioxygenase is effectively inhibited by targeting its apo-form (2018 · Proceedings of the National Academy of Sciences · 被引 212)
• Conformationally Constrained ortho-Anilino Diaryl Ureas: Discovery of 1-(2-(1′-Neopentylspiro[indoline-3,4′-piperidine]-1-yl)phenyl)-3-(4-(trifluoromethoxy)phenyl)urea, a Potent, Selective, and Bioavailable P2Y1 Antagonist (2013 · Journal of Medicinal Chemistry · 被引 71)
• Discovery of 2-(Phenoxypyridine)-3-phenylureas as Small Molecule P2Y1 Antagonists (2013 · Journal of Medicinal Chemistry · 被引 64)
• Nonclinical Toxicology Assessments Support the Chronic Safety of Dapagliflozin, a First-in-Class Sodium-Glucose Cotransporter 2 Inhibitor (2013 · International Journal of Toxicology · 被引 38)
• Identification of RIPK3 Type II Inhibitors Using High-Throughput Mechanistic Studies in Hit Triage (2019 · ACS Medicinal Chemistry Letters · 被引 37)
• Anion Gap, Anion Gap Corrected for Albumin, and Base Deficit Fail to Accurately Diagnose Clinically Significant Hyperlactatemia in Critically Ill Patients (2008 · Journal of Intensive Care Medicine · 被引 35)